MENU
VIVS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
VivoSim Lab (VIVS) Ownership - Who owns VivoSim Lab?
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
N/A
Phone
N/A
Employees
N/A
Web
N/A
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
3.82M
P/E Ratio
N/A
Total Cash
11.31M
Projected Growth
N/A
Total Debt
942K
Revenue
144K
Risk (Beta)
1.42
Dividend Yield
N/A
Total Cash/Share
4.35
Total Debt/Equity
0.03
Revenue/Share
0.10 USD as % of share price
Fundamentals
VIVS
Capitalization
3.82M
P/E Ratio
N/A
Risk (Beta)
1.42
Dividend Yield
N/A
Total Cash
11.3M
Total Cash/Share
4.35
Total Debt
942K
Total Debt/Equity
0.03
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.10%
Revenue
144K
ROE
N/A
Book Value
10.5M
P/B Ratio
0.36
Cash Flow
N/A
Earnings
-1.7
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
2K
Current Ratio
3.25
Current Revenue Per Employee
3642.86
Dividends Per Share - Security
N/A
EBITDA
-2.21M
Float
N/A
Float - Current
N/A
Gross Income Margin
100.00
Revenue To Assets
-23.70
Shares Held By Institutions
304K
Shares Outstanding - Current
2.6M
Total Liabilities
4.16M
Total Volume MTD
N/A
Value
1
Gain YTD
215.286
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a company which engages in developing and commercializing functional human tissues
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
N/A
Phone
N/A
Employees
N/A
Web
N/A